Results 31 to 40 of about 38,538 (308)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

open access: yesNature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku   +24 more
doaj   +1 more source

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]

open access: yes, 2017
Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena   +3 more
core   +1 more source

Modelling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion [PDF]

open access: yes, 2016
We have developed a mathematical framework for describing a bispecific monoclonal antibody interaction with two independent membrane-bound targets that are expressed on the same cell surface.
Argungu, Maryam   +8 more
core   +1 more source

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

open access: yesFrontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei   +3 more
doaj   +1 more source

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

open access: yesMolecular Therapy: Oncolytics, 2019
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes.
Jiayu Liu   +7 more
doaj   +1 more source

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy [PDF]

open access: yes, 2016
Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them.
Basilico, Cristina   +12 more
core   +2 more sources

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

open access: yesFrontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu   +27 more
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

open access: yes, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia   +16 more
core   +2 more sources

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

open access: yesCell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li   +3 more
doaj   +1 more source

Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices

open access: yesNature Communications, 2020
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy